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under the CC BY license (http://creaSummary Objectives: Despite over a century of research and the careful scrutiny of many
promising targets, there is currently no vaccine available for the prevention of Streptococcus
pyogenes infection. Through analysis of the protective, anti-streptococcal components of
pooled human immunoglobulin, we previously identified ten highly conserved and invariant
S. pyogenes antigens that contribute to anti-streptococcal immunity in the adult population.
We sought to emulate population immunity to S. pyogenes through a process of active vacci-
nation, using the antigens targeted by pooled human immunoglobulin.
Methods: Seven targets were produced recombinantly and mixed to form a multicomponent
vaccine (Spy7). Vaccinated mice were challenged with S. pyogenes isolates representing four
globally relevant serotypes (M1, M3, M12 and M89) using an established model of invasive dis-
ease.
Results: Vaccination with Spy7 stimulated the production of anti-streptococcal antibodies, and
limited systemic dissemination of M1 and M3 S. pyogenes from an intramuscular infection
focus. Vaccination additionally attenuated disease severity due to M1 S. pyogenes as evidenced
by reduction in weight loss, and modulated cytokine release.
Conclusion: Spy7 vaccination successfully stimulated the generation of protective anti-
streptococcal immunity in vivo. Identification of reactive antigens using pooled human immu-
noglobulin may represent a novel route to vaccine discovery for extracellular bacteria.
ª 2016 The Authors. Published by Elsevier Ltd on behalf of the The British Infection
Associat ion. This is an open access art icle under the CC BY l icense (http://
creativecommons.org/licenses/by/4.0/).Infectious Diseases & Immunity, Department of Medicine, Imperial College London, Du Cane Road,
el.: þ44 (0)20 3313 3135; fax: þ44 (0)20 3313 3394.
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Streptococcus pyogenes is often overlooked as a major
cause of human disease owing to the rarity of severe S.
pyogenes infection in the developed world. While the
attendant morbidity and mortality of invasive syndromes
such as necrotizing fasciitis and toxic shock are consider-
able, it is the rheumatogenic sequelae of non-invasive S.
pyogenes infections that represent the most pressing
global health burden. Such sequelae account for the ma-
jority of the >500,000 deaths per year worldwide attrib-
uted to streptococcal infection.1 Much of the burden of
rheumatic heart disease (RHD) exists in developing coun-
tries where poverty and limited access to prompt antibi-
otic treatment may contribute to the development of
autoimmunity.2 Although S. pyogenes remains exquisitely
sensitive to beta-lactam antibiotics, the development of
an effective vaccination is widely regarded as the most
reliable way to reduce the global S. pyogenes disease
burden.
Previous attempts to develop S. pyogenes vaccines
involved the use of single antigen formulations containing
well characterized virulence factors such as the M pro-
tein,3,4 C5a peptidase5 and, more recently, SpyCEP.6,7 How-
ever, there has been a recent shift towards the
development of multicomponent vaccines for pathogenic
bacteria, with the expectation that the inclusion of multi-
ple targets will ensure longevity of efficacy and coverage.
Several approaches to S. pyogenes vaccine antigen identifi-
cation have been described including, classical reverse vac-
cinology,7,8 serological identification of reactive surface
antigens9 and antigenome technology.10 One study used
three such approaches in conjunction with murine infection
experiments to identify six highly conserved protective an-
tigens, three of which (SpyCEP, streptolysin O and SpyAD)
were developed commercially as a multicomponent vac-
cine.11 With the exception of the M protein, no vaccine can-
didates have reached clinical trials to date.
We have characterized the streptococcal surface protein
targets of pooled human immunoglobulin (intravenous
immunoglobulin G, IVIG) using twenty different S. pyogenes
isolates representing four major emm/M types.12 IVIG is a
clinical blood product that is purified from the blood of
over one thousand healthy donors and therefore represents
a useful surrogate of population level immunity. Among the
identified S. pyogenes antigens, was a set of ten highly
conserved, invariant surface proteins that were conservedTable 1 The isolates used in this study.
Strain M-type CovRS s
H305 M1 CovS m
H330 M3 CovS m
H529 M12 WTc
H293 M89 WTc
a Stop at residue 318.
b Pro to Ser at residue 285.
c High SpeB producers.across not only the 20 isolates tested, but also all
genome-sequenced strains (Table 1). Several of these pro-
teins had previously been evaluated as vaccine antigens us-
ing established S. pyogenes infection models.5,7,10,11,13
Given the ability of human immunoglobulin to protect
against S. pyogenes infection, we hypothesized that a
multicomponent vaccine containing these conserved
invariant surface proteins would provide serotype indepen-
dent protection against S. pyogenes infection. Here seven
of the conserved, invariant targets of pooled human immu-
noglobulin were produced recombinantly and combined to
form a novel multivalent vaccine that was evaluated in an
experimental model of S. pyogenes infection. The data sug-
gest that vaccination with these seven antigens may be suf-
ficient to emulate the anti-streptococcal activity of pooled
human immunoglobulin.
Materials and methods
Bacterial strains and growth conditions
The S. pyogenes isolates used in this study are listed in
Table 1 and were routinely cultured from frozen stocks on
Columbia horse blood agar or in Todd-Hewitt broth at
37 C in 5% CO2. Strains were selected to represent four
clinically relevant serotypes circulating in Europe and North
America (Table 1). CovRS status of isolates was determined
by sequence analysis as previously described.14 SpeB pro-
duction was assessed by immunoblot analysis using a
1:1000 dilution of rabbit anti-SpeB antibody (Toxin Technol-
ogy) and a 1:80,000 dilution of HRP-conjugated goat anti-
rabbit IgG under standard conditions. Escherichia coli iso-
lates were routinely cultured at 37 C in LB broth or agar
supplemented with 100 mg/ml of ampicillin. Liquid E. coli
cultures were grown with agitation at 225 rpm.
Selection of vaccine antigens
Eight of the ten highly conserved and invariant strepto-
coccal surface antigens previously shown to be recognized
by IVIG were cloned and expressed in E. coli.12 Two proteins
were excluded; one on the grounds of its predicted cyto-
plasmic localization (chaperone protein DnaK), and the
other owing to the significant degree of sequence identity
to another antigen (nucleoside-binding protein). One of
the antigens proved recalcitrant to expression using the
methods applied (maltose/maltodextrin-binding protein).tatus Disease association
utanta Scarlet fever
utantb Puerperal sepsis and toxic shock
Toxic shock
Necrotizing fasciitis
452 M. Reglinski et al.The seven resulting recombinant antigens were combined
in equal amounts (10 mg/protein) to form a novel multicom-
ponent vaccine denoted Spy7.
Recombinant protein production
BamHI or NdeI-ended coding sequences for the selected
antigens were amplified from S. pyogenes gDNA (strain
H305) and cloned into pET-19b excluding any signal
sequence and cell wall anchor domain (Supplementary
Table 1). For pulA (Spy_1972) a 1.6 kb N-terminal fragment
was amplified by PCR and cloned into the TA cloning vector
PCR 2.1 (Invitrogen) to facilitate NdeI digestion. For scpA, a
premature stop codon was inserted at amino acid 720 by
site directed mutagenesis (QuikChange II XL, Agilent) to
prevent removal of the N-terminal propeptide.15 Antigens
were produced by IPTG-induced overexpression in One
Shot BL21 (DE3) Chemically Competent E. coli (Invitrogen)
according to the manufacturer’s instructions. The induced
BL21 cells were lysed with BugBuster (Novagen) and pro-
teins were purified using the Ni-NTA purification system (In-
vitrogen) according to the manufacturer’s instructions.
Active immunization and cytokine analysis
Age matched (5e6 week old) female FVB/N mice (Charles
River Laboratories International) housed in cages of six
were vaccinated intramuscularly (left flank) with 70 mg of
protein, emulsified 1:1 with Freund’s complete adjuvant.
Booster immunizations were given at 21 (right flank) and 35
days (left flank) in Freund’s incomplete adjuvant. Controls
were immunized with PBS and adjuvant alone. Tail bleeds
were performed on day 41 (one day prior to infection) to
confirm seroconversion. Mice were challenged intramuscu-
larly (right flank) with w1  107 CFU of S. pyogenes sero-
types: M1, (strain H305); M3, (strain H330); M12, (strain
H529) and M89, (strain H293) on day 42. At 24 h post infec-
tion the mice were weighed and culled, and blood was
removed by cardiac puncture. The infected thigh, draining
inguinal lymph node, spleen and liver were dissected,
weighed and homogenized. Bacterial loads were quantified
by plating. Challenge experiments were either conducted
as a single study involving 12 mice per group (M1 and M3
challenges) or as two studies involving 6 mice per group
(12 mice per group total, M12 and M89 challenges). Plasma
cytokines in blood from infected mice were quantified using
a mouse cytokine 20-plex panel (Invitrogen) according to
the manufacturer’s instructions.
Seroconversion ELISAs
Plates were coated with 50 ml/well of either whole S. pyo-
genes cells (resuspended to an A600 of 0.5 in PBS) or 1 mg/
well of recombinant protein and probed with plasma recov-
ered on day 41 post-vaccination (prior to infection chal-
lenge). Bound antibodies were detected using 1:2000-
diluted HRP-conjugated goat anti-mouse IgG (Sigma-
eAldrich) and 50 ml/well tetramethylbenzidine (Sigma-
eAldrich). The reaction was stopped through addition of
50 ml of 1 M H2SO4 and absorbance at 450 nm was measured.
To determine the development and durability of the humanantibody response to Spy7 antigens, ELISA plates were
coated with 1 mg/well of recombinant protein and probed
with 10-fold dilutions (1:1000e1:1,000,000) of acute and
convalescent serum from a patient who had recovered
from an S. pyogenes bacteraemia 8 weeks earlier, and
who had not received IVIG. Bound antibodies were de-
tected using a 1:2000 dilution of HRP-conjugated goat
anti-human IgG. Normal human serum from a healthy adult
was included as a control.
Lymphocyte proliferation assays
For lymphocyte proliferation assays, female FVBn mice
were vaccinated with a single 70 mg dose of Spy7 (n Z 3)
or sham vaccinated with PBS and adjuvant alone (n Z 1).
Draining inguinal lymph nodes were harvested at 12 d and
disaggregated into single cell suspensions using a 70 mm cell
sieve into RPMI (supplemented with 10% FBS, 2 mM L-gluta-
mine and 500 mg/ml penicillinestreptomycin). 2 105 cells/
well were co-incubated in triplicate with 1 mg/well of anti-
gen, or 28 mg/well of Spy7, in a final volume of 200 ml at
37 C for 48 h. Cellular proliferation was measured using a
colourimetric BrdU assay (Roche) according to the manufac-
turer’s instructions. Absorbances generated by cells from
Spy7 vaccinated animals were corrected for non-specific
reactivity by subtraction of the mean absorbance generated
by cells from the sham vaccination experiment.
Ethics
All animal procedures were approved by the local ethical
review process at Imperial College London and conducted in
accordance with the relevant, UK Home Office approved,
project licence. The collection and use of anonymized
samples from patients with infection was approved by the
relevant research ethics committee (NRES 06/Q0406/20).
Statistical analysis
Data were analysed using GraphPad Prism (GraphPad
Software Inc.) and are displayed as median and range, or
mean and standard deviation. Statistical significance was
accepted where *p < 0.05 using a two-tailed ManneWhit-
ney U (two groups) or KruskaleWallis one-way ANOVA with
Dunn’s post-test (three groups).
Results
Vaccination with Spy7 generates anti-streptococcal
antibodies
To determine the efficacy of Spy7, female FVB/N mice were
vaccinated with Spy7 or sham vaccinated with PBS and
adjuvant alone. A third group was vaccinated with the
SpyCEP fragment CEP-5 that has previously been shown
to provide protection against experimental S. pyogenes
infection.6,16 41 d following the start of the vaccination
protocol, the anti-streptococcal activity of plasma from
Spy7-vaccinated and sham-vaccinated mice was compared
by whole bacterial cell ELISA (Fig. 1A). Comparison of the
Figure 1 Vaccination with Spy7 stimulates the generation of anti-streptococcal antibodies. Plates were coated with (A) live
M1 S. pyogenes (strain H305) or (BeI) 1 mg/well of recombinant protein and probed with a 1:8000 dilution of murine plasma recov-
ered from Spy7 vaccinated (open triangles), CEP-5 vaccinated (open circles) or sham vaccinated (closed squares) mice. Bound
antibodies were detected using a 1:2000 dilution of HRP-conjugated goat anti-mouse IgG. A) *p < 0.05 KruskaleWallis (Dunns
post-test) BeI) *p < 0.05 two-tailed ManneWhitney U.
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generated a stronger anti-streptococcal antibody response
than CEP-5 alone, most likely resulting from the inclusion
of multiple surface protein targets in the Spy7 formulation.
Each of the seven recombinant vaccine components also re-
acted with plasma from Spy7-vaccinated mice; indicating
that each antigen had stimulated the humoural immune
response, and thus was potentially contributing to the
anti-streptococcal antibody response elicited by Spy7
(Fig. 1BeH). These levels of reactivity were comparable
with the anti-CEP-5 reactivity measured in the mice vacci-
nated with CEP-5 alone indicating that the levels of circu-
lating antibody generated by Spy7 vaccination may not
necessarily be improved by increasing the concentration
of the individual antigens (Fig. 1I).
The development and durability of the human antibody
response to the Spy7 components was examined by ELISA,
using acute and convalescent serum from a patient who had
recovered from an invasive M1 S. pyogenes bacteraemia,
and normal human serum from a healthy adult
(Supplementary Fig. 1). In contrast to the acute sample (ob-
tained on the day of presentation), convalescent serum
(obtained 8 weeks after presentation) reacted strongly
against six of the seven Spy7 components. The seventh
component (hypothetical membrane associated protein,
Spy_1037), displayed only modest reactivity. C5a peptidase
(Spy_2010) and SpyAD (Spy_0269) were also shown to react
strongly with the normal human serum sample, suggesting
that once primed, the humoural immune response to these
antigens may persist in circulation for extended periods.Vaccination with Spy7 prevents dissemination of
serotype M1 and M3 S. pyogenes
Having established that Spy7 and CEP-5 had both elicited a
strong humoural immune response, the vaccinated mice
were challenged intramuscularly with 1  107 CFU of live
M1 S. pyogenes and the ability of each vaccine to prevent
bacterial dissemination was assessed in comparison with
sham vaccination. Percentage weight loss was lower in
both the Spy7 and CEP-5 vaccinated mice compared to
the sham vaccinated group, consistent with reduced illness
severity (Fig. 2A). The bacterial burden in the infected
thigh was comparable between groups (Fig. 2B). While a
trend to reduction in bacterial burden in the inguinal lymph
node was apparent in both groups, a statistically significant
difference was only recorded between the CEP-5 vacci-
nated and sham vaccinated groups (Fig. 2C). Vaccine-
induced immunity was sufficient to inhibit systemic bacte-
rial dissemination to the spleen (Fig. 2D), liver (Fig. 2E),
and blood (Fig. 2F) of the Spy7-vaccinated mice compared
with the sham-vaccinated group. In contrast, no significant
reduction in bacterial burden was reported in the spleen or
liver of the CEP-5 vaccinated mice, when compared to the
sham vaccinated group.
The ability of Spy7 to provide protection against other S.
pyogenes serotypes was then assessed using a representa-
tive strain from three other contemporary serotypes of S.
pyogenes currently circulating in Europe and North America
(M3, M12 and M89). In contrast to the previous experiment,
no difference in percentage weight loss was observed be-
tween the Spy7 vaccinated and sham vaccinated animals
Figure 2 Spy7 prevents dissemination of M1 S. pyogenes from an intramuscular focus of infection. Three groups of twelve
age-matched female FVB/N mice were vaccinated with Spy7 (open triangles) or CEP-5 (open circles), or sham vaccination with
PBS and adjuvant alone (closed squares) and challenged with w1  107 CFU/mouse of M1 S. pyogenes (strain H305). Solid lines
indicate the median CFU recovered from each organ 24 h post infection. *p < 0.05 KruskaleWallis (Dunns post-test) ND: Not
Detected.
454 M. Reglinski et al.infected with serotype M3 S. pyogenes (Fig. 3A). The bacte-
rial burden in the infected thigh and draining lymph node
remained comparable between groups (Fig. 3B and C).
Spy7-induced immunity limited bacterial dissemination to
the spleen (Fig. 3D) and liver (Fig. 3E) but had no discern-
ible effect on bacterial burden in the blood (Fig. 3F).
Very limited systemic dissemination occurred following
intramuscular infection with M12 and M89 S. pyogenes, re-
sulting in very low bacterial counts at each organ site and
thus making it difficult to adequately compare bacterial
spread (Supplementary Fig. 2).
Impact of vaccination on cytokine and chemokine
responses
Having established that Spy7 was capable of limiting
systemic dissemination in an M1 and M3 infection model,
plasma cytokine profiles of the Spy7- and sham-vaccinated
groups were compared 24 h post-infection challenge to
determine the effect of vaccination on proinflammatory
cytokine production in response to infection (Fig. 4).
Consistent with changes in weight loss, vaccination with
Spy7 reduced levels of IL-6, a recognized marker of
severity, in mice infected with M1 S. pyogenes, though
not those infected with M3 S. pyogenes (Fig. 4A). Unlike
IL-6, levels of the immunomodulatory cytokine IL-10 were
higher in the Spy7-vaccinated M1 group although the signif-
icance of this is unclear at present (Fig. 4B). Vaccination
also led to a reduction in a number of inflammatorychemokines and cytokines involved in leucocyte chemoat-
traction and activation (KC and MCP-1) though this was
not a universal finding (Fig. 4C and D). This included a clear
impact on IL-5 in both M1- and M3-infected mice (Fig. 4E), a
cytokine previously linked to superantigen production in
experimental S. pyogenes infection.17 The proinflammatory
cytokine TNF-alpha was undetectable in all mice, consis-
tent with previous data from this model.18 Unexpectedly,
when comparing mice infected with M1 or M3 S. pyogenes,
levels of IFN-g, IP-10 and MIG in M3-infected mice exceeded
levels measured in M1-infected mice by an order of magni-
tude, despite bacteraemia being most frequently detected
in M1-infected mice (Supplementary Table 2).
Vaccination with Spy7 induces T cell responses
To determine if Spy7 vaccination can induce T cell re-
sponses, a small cohort of mice was vaccinated with a
single dose of Spy7, and cells from the draining lymph
node were re-stimulated ex vivo with Spy7, or the individ-
ual Spy7 antigens. Although from only a small number of
mice, the data indicated that Spy7 vaccination induced T
cell responses to C5a peptidase (Spy_2010), SpyAD
(Spy_0269), cell surface protein (Spy_0843) and, to a
more limited extent, nucleoside-binding protein
(Spy_1228) (Fig. 5). Together these data suggest that the
humoural immune response stimulated by several of the
Spy7 antigens may be accompanied by a cognate T cell
response.
Figure 3 Spy7 prevents dissemination of M3 S. pyogenes from an intramuscular focus of infection. Two groups of twelve age-
matched female FVB/N mice were vaccinated with Spy7 (open triangles) or sham vaccination with PBS and adjuvant alone (closed
squares) and challenged withw1  107 CFU/mouse of M3 S. pyogenes (strain H330). Solid lines indicate the median CFU recovered
from each organ 24 h post infection. *p < 0.05 two-tailed ManneWhitney U. ND: Not Detected.
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The human blood product IVIG provides an intriguing sur-
rogate for population-based immunity to S. pyogenes. Here
we attempted to emulate the protection afforded by exper-
imental IVIG administration using a combination vaccine
incorporating seven of the most highly conserved and
invariant antigens recognized by the reagent.12 Our data
demonstrate that Spy7 stimulates a strong humoural
immune response in vivo, and provides demonstrable
protection against two of the most common contemporary
S. pyogenes serotypes (M1 and M3). While inadequate
dissemination of two additional serotypes (M12 and M89)
prevented reliable appraisal of the efficacy of Spy7, the
available data suggests that the vaccine may indeed pro-
vide some protection against these serotypes in vivo.
Historically, attempts to develop an S. pyogenes vaccine
have revolved around the use of the M protein, a multifac-
eted virulence factor that stimulates type specific immu-
nity during natural infection.19 Although the existence of
over 100 distinct serotypes initially impeded the develop-
ment of an effective M protein vaccine, recent analyses
have demonstrated that the antigenic diversity of different
M protein isoforms may be less extensive than was once
thought,20,21 and several approaches to M protein-based
vaccine design have been evaluated.4,22,23 In addition tothe M protein, several other antigens have been tested in
isolation as vaccine candidates, including six of those
included in this study (Table 2). Of these, C5a peptidase,
cell surface protein, and SpyAD showed protective effi-
cacy,5,11,13 while oligopeptide-binding protein, putative
pullulanase, and hypothetical membrane associated pro-
tein were not protective.10,11 Although immunization with
C5a peptidase has been shown to reduce experimental
nasopharyngeal colonization, data from invasive S. pyo-
genes infection models yield conflicting results.5,7,11
Notwithstanding the success of some single antigen formu-
lations, the risk of vaccine escape mutants and/or clones
that do not express the target antigen arising within the
vaccinated human population provides a rationale for the
combination of several targets to promote consistent clear-
ance of highly pathogenic organisms such as S. pyo-
genes.10,11 Indeed the availability of S. pyogenes genome
data has given rise to a series of systems-based approaches
to vaccine design, which have resulted in the development
of several combination vaccines.7,10,11 Although few of the
antigens described herein are reported to protect against S.
pyogenes infection in isolation, this does not discount their
usefulness in novel formulations where the synergistic ef-
fects of many targets may contribute to the overall efficacy
of the vaccine, inducing neutralizing and opsonic activities.
This is particularly true of formulations such as Spy7, which
includes proteins involved in complement escape (C5a
Figure 4 Vaccination with Spy7 reduces systemic inflammation during experimental S. pyogenes infection. Blood was recov-
ered from the infected animals by cardiac puncture 24 h post infection and the cytokine concentration in plasma was quantified by
multiplex analysis. Solid lines indicate the median concentration of each cytokine present within the Spy7 (open triangles) or Sham
(closed squares) vaccinated animals. M1 (H305), n Z 12; M3 (H330), n Z 9. *p < 0.05 two-tailed ManneWhitney U. ND: Not
Detected.
456 M. Reglinski et al.peptidase),5 adhesion (SpyAD and putative pullulanase)24,25
and lipoproteins presumed to facilitate substrate binding
and nutrient acquisition (maltose/maltodextrin-binding
protein, oligopeptide-binding protein and nucleoside-
binding protein).
Vaccination with Spy7 reduced disease severity in mice
infected with M1 S. pyogenes, as evidenced by reduced IL-6
levels, though this effect could not be demonstrated in
mice infected with M3 S. pyogenes. Disease severity overall
may have been greater in M1-infected mice, which werebacteraemic at the 24 h time point, and we speculate
that this may have augmented any effect of vaccination
on cytokines such as IL-6. Vaccination also influenced the
levels of a number of leucocyte chemoattractants such as
the IL-8 homologue KC, MCP-1, and IL-5 however, any
impact on these cytokines and chemokines may reflect
the reduction in bacterial counts observed in the vacci-
nated groups compared with controls. Of particular note
was the effect of vaccination on serum levels of IL-5. IL-5
has previously been shown to be elevated in models of S.
Figure 5 Vaccination with Spy7 induces a T cell response
to Spy7 and its components. The proliferative response of T
cells from the draining inguinal lymph node of mice vaccinated
intramuscular ly with Spy7 was measured fol lowing
re-stimulation with Spy7 or the individual vaccine antigens.
Symbols differentiate different antigens. Data from individual
mice are displayed as mean  SD of triplicate absorbance read-
ings corrected for non-specific reactivity by subtraction of the
mean absorbance generated by cells from a single sham-
vaccinated mouse.
An effective multicomponent vaccine for S. pyogenes 457pyogenes infection potentially in response to superanti-
gens,17 although a link with severity and bacterial burden
has not been recognized.
Clearly Spy7 would require further refinement and
appraisal prior to development of the vaccine, including
evaluation of alternative adjuvants that are better suited
for use in human vaccination, and evaluation in naso-
pharyngeal infection. Notably, the methodology em-
ployed to identify the Spy7 components did not permit
identification of non-proteinaceous antigens such as the
group A carbohydrate that may enhance vaccine efficacy
and/or coverage.26,27 While inclusion of all seven anti-
gens was considered the simplest preliminary approachTable 2 Selection of Spy7 subunits. Spy7 subunits are displayed
Gene/ORF Protein product
scpA, M5005_Spy1715, Spy_2010 C5a peptidase
dnaK, M5005_Spy1498, Spy_1760 Chaperone protein DnaKa
malE, M5005_Spy1058, Spy_1294 Maltose/maltodextrin-binding
oppA, M5005_Spy0249 Oligopeptide-binding protein
M5005_Spy0137 Nucleoside-binding proteinc
pulA, SPy_1972 Putative pullulanase
M5005_Spy0942, Spy_1228 Nucleoside-binding proteinc
M5005_Spy0762, Spy_1037 Hypothetical membrane asso
protein
M5005_Spy0651, Spy_0843 Cell surface protein
prgA, M5005_Spy0229, Spy_0269 SpyAD
a Chaperone protein DnaK was excluded from Spy7 owing to the cyt
b Maltose/maltodextrin-binding protein was cloned but could not be
c Nucleoside-binding lipoproteins Spy_1228 and M5005_Spy0137 sha
these targets (Spy_1228) was included in Spy7.
d Prior references are given for antigens previously assessed in actito development of a multicomponent vaccine, recombi-
nant production and purification of such a large number
of molecules may present a significant challenge.
Although each component of Spy7 was shown to stimulate
humoural immunity; both upon experimental administra-
tion and, in most cases, during natural S. pyogenes infec-
tion, only three (C5a peptidase, SpyAD and cell surface
protein) could be shown to generate a cognate T cell
response, and were capable of inducing appreciable T
cell proliferation upon re-stimulation of lymph node cells
from Spy7 vaccinated animals. Interestingly two of these
components (C5a peptidase and SpyAD) also reacted
strongly with serum from a normal adult, suggesting
that the antibody response to these proteins may be
long lived. Based on these preliminary findings, it may
be appropriate to further refine the components of
Spy7 prior to development of the vaccine. Alternatively,
it may be possible to produce a chimeric molecule that
includes the major antigenic domains of all seven pro-
teins which may further reduce the risk of vaccine escape
mutants evolving, by increasing the number of sponta-
neous mutations required to facilitate immune evasion.
Importantly, murine Spy7 antiserum demonstrated no
discernible reactivity with human heart valve tissue using
an ELISA based assay, suggesting an absence of cross
reactive epitopes within any of the selected antigens
(data not shown).
Several previous studies have attempted to characterize
the S. pyogenes surface proteome, and/or the antigens that
are recognised by human serum, yielding a large number of
potential vaccine candidates.9,10,28,29 The proteins identi-
fied as potential vaccine candidates in such studies are
however influenced by the method employed for screening
of target antigens, which have included non-native protein
preparations, peptide epitopes, and/or sera of unknown
protective activity in previous studies. The current study
was unique insofar as the IVIG preparation used to identify
potential vaccine candidates was known to be highly
protective both in vitro and in vivo. The use of a highlyin bold.
Prior referenced Efficacy reported in vivo
5,7,11 Carriage: Increased clearance
Invasive: Model dependent
n/a n/a
proteinb n/a n/a
11 No
n/a n/a
10 No
n/a n/a
ciated 11 No
13 Invasive: Increased Survival
11 Invasive: Increased Survival
oplasmic location of the protein.
expressed recombinantly.
red a significant degree of amino acid identity, thus only one of
ve, in vivo vaccination experiments only.
458 M. Reglinski et al.protective preparation of IVIG as an initial screening
technique provided a highly efficient route to vaccine
antigen identification in contrast to other studies where
large scale in vivo experiments are employed to screen
candidates.10,11
Selection of the subunits for vaccination in the current
study was systematic and objective and, unlike previous
studies, was not influenced by the novelty of the identified
antigens, or previous data relating to their efficacy.
Whether inclusion of antigens with previously-
demonstrated protective action is of particular importance
for the functionality of Spy7 remains unclear. The study
enabled rapid identification of potential vaccine candidates
without preliminary evaluation in animal models, using an
approach that could be extended to other common path-
ogens. While individual components of Spy7 have previously
been evaluated as vaccine antigens, the current study
provides much needed rationale for inclusion of these in
future combination vaccines.
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